News

Antoni Vilaseca, MD, Hospital Clínic de Barcelona

Videos

Novel Erdafitinib Intravesical Delivery System Showed Safety, Efficacy for Patients With Non–Muscle-Invasive Bladder Cancer With Select FGFR Alterations

11/01/2023

Antoni Vilaseca , MD;

Antoni Vilaseca, MD, discusses the novel erdafinitib delivery system for patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.

Antoni Vilaseca, MD, discusses...

11/01/2023

Oncology

News

Enfortumab Vedotin Demonstrates Long-Term Survival Benefits Among Patients With Advanced Urothelial Carcinoma

10/16/2023

Allison Casey ;

In long-term follow-up data from the phase 3 EV-301 trial, enfortumab vedotin continued to show survival benefits over chemotherapy among patients with previously treated advanced urothelial carcinoma.

In long-term follow-up data from...

10/16/2023

Oncology

News

Gemcitabine-Docetaxel as a Renal-Sparing Options for Patients With High-Grade Upper Tract Urothelial Carcinoma

10/16/2023

Allison Casey ;

A retrospective review found gemcitabine-docetaxel to be a safe and effective renal-sparing treatment option for certain patients with high-grade upper tract urothelial carcinoma.

A retrospective review found...

10/16/2023

Oncology

News

Gemcitabine and Cisplatin Plus Nivolumab as Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer

10/10/2023

Allison Casey ;

According to results from a phase 2 study, patients with muscle-invasive bladder cancer who achieved a clinical complete response to gemcitabine, cisplatin and nivolumab following TURBT were able to avoid radical cystectomy, with favorable...

According to results from a...

10/10/2023

Oncology

News

No Benefit From Novel Atezolizumab Combination Treatments Among Patients With Platinum-Refractory Metastatic Urothelial Carcinoma

09/19/2023

Allison Casey ;

In a phase 1b/2 trial, regimens of atezolizumab plus magrolimab, niraparib, or tocilizumab did not meet the necessary response rate criteria for further development among patients with platinum-refractory metastatic urothelial carcinoma.

In a phase 1b/2 trial, regimens...

09/19/2023

Oncology

News

Durvalumab Added to Standard of Care Improves Survival Outcomes for Patients With Muscle-Invasive Urothelial Carcinoma

09/05/2023

Allison Casey ;

According to a phase 2 trial, the additional of durvalumab to neoadjuvant chemotherapy and as an adjuvant treatment following surgery improved event-free survival and overall survival for patients with resectable, muscle-invasive urothelial...

According to a phase 2 trial,...

09/05/2023

Oncology

News

Concurrent Chemoradiotherapy May Improve Overall Survival Among Patients With High Grade Non-Muscle Invasive Bladder Cancer

08/08/2023

Allison Casey ;

According to a retrospective study, concurrent chemoradiotherapy may improve the overall survival of patients with high-grade non-muscle invasive bladder cancer confined to the lamina propia, compared with radiation alone.

According to a retrospective...

08/08/2023

Oncology

News

Bladder-Sparing Trimodal Therapy As a Potential Treatment Option for Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer

07/31/2023

Allison Casey ;

A retrospective analysis found no difference in survival outcomes between radical cystectomy and radical dose radiotherapy among patients with clinically node-positive nonmetastatic bladder cancer.

A retrospective analysis found...

07/31/2023

Oncology

News

Olaparib Showed Limited Antitumor Activity Among Patients With Metastatic Urothelial Carcinoma and DNA Damage Response Alterations

07/20/2023

Allison Casey ;

In a phase 2 study, olaparib demonstrated limited antitumor activity among patients with metastatic urothelial cancer harboring alterations in DNA damage response genes.

In a phase 2 study, olaparib...

07/20/2023

Oncology

News

Enfortumab Vedotin Plus Pembrolizumab Demonstrates Promising Response Rates, Durability Among Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma

07/17/2023

Allison Casey ;

Results from the phase 1b/2 EV-103 trial found high response rates with promising durability among cisplatin-ineligible patients with urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab in the first-line.

Results from the phase 1b/2...

07/17/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology